Current Role of Lamivudine Regarding Therapeutic Response and Resistance in Children with Chronic Hepatitis B
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: To identify the predictive factors of long-term therapeutic response or resistance to lamivudine treatment in children and adolescents with chronic hepatitis B. Methods: Eighty one children and adolescents with chronic hepatitis B were included, who received lamivudine treatment for at least 6 months. Their condition was monitored for at least 12 months (12-88 months) thereafter. Twenty one (25.9%) were preschool children (age≤6). For patients who had developed HBeAg seroconversion or breakthrough, univariate and multivariate analyses were used to identify the effects of age, gender, pretreatment alanine aminotransferase (ALT) and hepatitis B virus DNA levels. Results: HBeAg seroconversion occurred in 49 (60.5%) of the 81 patients after the initiation of the lamivudine therapy. In 65 patients whom were monitored for over 24 months, the seroconversion rate was significantly higher in younger patients (p=0.040), especially in those patients of preschool age (age≤6, p=0.031). The seroconversion rate was significantly higher in higher pretreatment ALT (p=0.003). The breakthrough occurred in 21 (25.9%) of the 81. The breakthrough rate was lower in younger aged patients (age≤6), and with higher pretreatment ALT levels, but no significant difference. Conclusion: Younger age is a good predictor of HBeAg seroconversion in children with long-term lamivudine treatment as well as high pretreatment ALT levels. (Pediatr Gastroenterol Hepatol Nutr 2013; 16: 80∼88)
Abstract
Purpose: To identify the predictive factors of long-term therapeutic response or resistance to lamivudine treatment in children and adolescents with chronic hepatitis B. Methods: Eighty one children and adolescents with chronic hepatitis B were included, who received lamivudine treatment for at least 6 months. Their condition was monitored for at least 12 months (12-88 months) thereafter. Twenty one (25.9%) were preschool children (age≤6). For patients who had developed HBeAg seroconversion or breakthrough, univariate and multivariate analyses were used to identify the effects of age, gender, pretreatment alanine aminotransferase (ALT) and hepatitis B virus DNA levels. Results: HBeAg seroconversion occurred in 49 (60.5%) of the 81 patients after the initiation of the lamivudine therapy. In 65 patients whom were monitored for over 24 months, the seroconversion rate was significantly higher in younger patients (p=0.040), especially in those patients of preschool age (age≤6, p=0.031). The seroconversion rate was significantly higher in higher pretreatment ALT (p=0.003). The breakthrough occurred in 21 (25.9%) of the 81. The breakthrough rate was lower in younger aged patients (age≤6), and with higher pretreatment ALT levels, but no significant difference. Conclusion: Younger age is a good predictor of HBeAg seroconversion in children with long-term lamivudine treatment as well as high pretreatment ALT levels. (Pediatr Gastroenterol Hepatol Nutr 2013; 16: 80∼88)
참고문헌 (25)
- Bortolotti F, "Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood", Gastroenterology, 99, pp.805~810 (1990)
- Conjeevaram HS, "Management of chronic viral hepatitis in children", J Pediatr Gastroenterol Nutr, 20, pp.365~375 (1995)
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- Choe BH, "Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better", J Pediatr Gastroenterol Nutr, 44, pp.92~98 (2007)
- Hom X, "Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection", Pediatr Infect Dis J, 23, pp.441~445 (2004)
- Liberek A, "Lamivudine therapy for children with chronic hepatitis B", World J Gastroenterol, 12, pp.2412~2416 (2006)
- 박능화, "만성 B형 간질환 환자에서 라미부딘의 치료 효과 및 예측인자", 대한소화기학회지, 42(4), pp.157~165 (2003), 대한소화기학회
- Leung NW, "Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy", Hepatology, 33, pp.1527~1532 (2001)
- Yoon SK, "Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion", Intervirology, 48, pp.341~349 (2005)
- Hartman C, "Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon", J Pediatr Gastroenterol Nutr, 43, pp.494~498 (2006)
- Sokal EM, "Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B", Hepatology, 43, pp.225~232 (2006)
- Jonas MM, "International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B", N Engl J Med, 346, pp.1706~1713 (2002)
- Sokal EM, "Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial", Gastroenterology, 114, pp.988~995 (1998)
- Lau DT, "Long-term therapy of chronic hepatitis B with lamivudine", Hepatology, 32, pp.828~834 (2000)
- Song BC, "Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea", Hepatology, 32, pp.803~806 (2000)
- Hong SP, "Long-term efficacy and durability of lamivudine therapy in patients with chronic hepatitis B", Korean J Hepatol, 7, pp.423~431 (2001)
- Broderick A, "Management of hepatitis B in children", Clin Liver Dis, 8, pp.387~401 (2004)
- 김정미, "소아 만성 B형간염에서 라미부딘 치료 후 연령에 따른 B형간염바이러스 표면항원 소실률 비교", Clinical and Molecular Hepatology, 15(2), pp.168~178 (2009), 대한간학회
- Figlerowicz M, "Filipowicz M, Bujnowska A, Mozer-Lisewska I, Słuzewski W. Efficacy of lamivudine in the treatment of children with chronic hepatitis B", Hepatol Res, 31, pp.217~222 (2005)
- Dikici B, "Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study", J Gastroenterol Hepatol, 19, pp.127~133 (2004)
- Dikici B, "Which combination should be preferred in the management of children with chronic hepatitis B infection?", J Clin Gastroenterol, 39, pp.745~746 (2005)
- Ozgenç F, "Effect of long-term lamivudine in chronic hepatitis B virus-infected children", Antivir Ther, 9, pp.729~732 (2004)
- Choe BH, "Lamivudine treatment in children with chronic hepatitis B: long-term therapeutic Response, optimal duration and resistance. the 39th Annual Meeting of ESPGHAN; 2006; Dresden, Germany", J Pediatr Gastroenterol Nutr, pp.E64~65 (2006)
- Suk Jin Hong, "Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children", Pediatric Gastroenterology, Hepatology & Nutrition, 15(2), pp.63~73 (2012), 대한소아소화기영양학회
- Chu M, "Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B", J Pediatr Gastroenterol Nutr, 55, pp.648~652 (2012)